Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (387)	1/9/2003 1:39:15 PM
From: scaram(o)uche	Respond to of 598

Great presentation. Doing biotech the way it is meant to be done, right into the teeth of market hell. Won't be boring.

To: keokalani'nui who wrote (387)	1/10/2003 3:25:44 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 598

I also came away feeling better about T67, particularly the possibility of a relatively fast and low cost evaluation. With high 6 month mortality for HCC, the ability to demonstrate improved survival rates (or the failure to do so) should come fairly quickly. I think this gives a very favorable upside/downside risk profile. If the data look good, they can file for fast track approval. If they don't look good, they can cut their losses and move on. T487 also sounds promising, especially given the claim of "no side effects" in Phase I. T131. I appreciated getting more background on this one. Given the promise of efficacy with a significantly improved side effects/safety profile in a huge market, this sounded like a potential blockbuster. The IND candidates forecast also sounded very positive, especially the one for lipid disorders that dramatically increases HDL. My take on the decision to keep 6 candidates in the ready state is that they are trying to manage development costs ahead of their first big cash generator. In that regard, the partnering program may be very valuable in having large pharma support in funding research and conceivably providing more cash via purchases of larger interests in the projects. The image that comes to mind around TLRK's R&D program is that of Luther Burbank accelerating his development of new plant varieties by speeding up his ability to recognize and weed out early those that would not work. This allowed him to shift resources to support those showing the best potential and explore new possibilities. The willingness to cut losses and can projects that aren't working is an important feature in improving the overall effectiveness of the development program. It also helps inspire confidence in the candidates that they decide to keep.